Floatz logo

Avzo-103

Locally Advanced

Avenzo Therapeutics, Inc.Phase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Locally Advanced cohort.

Asset / SponsorPhaseRating
Irinotecan
Salah Azaïz Cancer Institute
Phase 3BB
Bms-907351
Centre Francois Baclesse
Phase 4BB
(+)-VINCRISTINE
Amgen
Phase 3BB
Epirubicin
PMV Pharmaceuticals, Inc
Phase 2B
Conatumumab
Amgen
Phase 2B

View all 26 →

Same molecule, other indications

Avzo-103 is also rated in:

urothelial carcinomaDormant
CC
Indicative ·
45 / 100
View asset →
Solid Tumor CancerDormant
CC
Indicative ·
43 / 100
View asset →
metastatic malignant neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →